To assess whether serum osteoprotegerin (OPG) and/or fetuin-A predict mortality and cardiovascular (CV) morbidity and mortality in hemodialysis patients. Multicenter, observational, prospective study that included 220 hemodialysis patients followed up for up to 6 years. Serum OPG and fetuin-A levels were measured at baseline and their possible association with clinical characteristics, CV risk biomarkers, carotid ultrasonographic findings, as well as their association with overall and CV mortality and CV events were assessed. During a mean follow-up of 3.22 ± 1.91 years, there were 74 deaths (33.6%) and 86 new cardiovascular events. In the Kaplan-Meier survival analysis, the highest tertile of OPG levels was associated with higher overall m...
Background and Objectives: Osteoprotegerin (OPG), a potent osteoclast activation inhibitor, decrease...
Biomarkers can help physicians identify subjects with an increased cardiovascular risk. Apart from t...
BACKGROUND:Fetuin A, a circulating inhibitor of ectopic calcification, is downregulated in hemodialy...
To assess whether serum osteoprotegerin (OPG) and/or fetuin-A predict mortality and cardiovascular (...
BACKGROUND: To assess whether serum osteoprotegerin (OPG) and/or fetuin-A predict mortality and card...
Background: Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by ca...
BACKGROUND/AIMS: Osteoprotegerin (OPG) and fetuin-A are vascular calcification regulators that may b...
Cardiovascular disease is the leading cause of death in chronic kidney disease and hemodialysis popu...
BackgroundCardiovascular disease is the leading cause of death in chronic kidney disease and hemodia...
Expression of bone proteins resulting from transdifferentiation of vascular smooth muscle cells into...
Dept. of Medicine/석사Backgrounds : Osteoprotegerin (OPG) is known to regulate bone mineral metabolism...
Background Vascular calcification is common among patients undergoing dialysis and is associated wit...
Cardiovascular calcifications (CVC) are frequently observed in chronic kidney disease (CKD) patients...
Calcifying atherosclerosis is an active process, which is controlled by calcification inhibitors and...
Calcifying atherosclerosis is an active process, which is controlled by calcification inhibitors and...
Background and Objectives: Osteoprotegerin (OPG), a potent osteoclast activation inhibitor, decrease...
Biomarkers can help physicians identify subjects with an increased cardiovascular risk. Apart from t...
BACKGROUND:Fetuin A, a circulating inhibitor of ectopic calcification, is downregulated in hemodialy...
To assess whether serum osteoprotegerin (OPG) and/or fetuin-A predict mortality and cardiovascular (...
BACKGROUND: To assess whether serum osteoprotegerin (OPG) and/or fetuin-A predict mortality and card...
Background: Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by ca...
BACKGROUND/AIMS: Osteoprotegerin (OPG) and fetuin-A are vascular calcification regulators that may b...
Cardiovascular disease is the leading cause of death in chronic kidney disease and hemodialysis popu...
BackgroundCardiovascular disease is the leading cause of death in chronic kidney disease and hemodia...
Expression of bone proteins resulting from transdifferentiation of vascular smooth muscle cells into...
Dept. of Medicine/석사Backgrounds : Osteoprotegerin (OPG) is known to regulate bone mineral metabolism...
Background Vascular calcification is common among patients undergoing dialysis and is associated wit...
Cardiovascular calcifications (CVC) are frequently observed in chronic kidney disease (CKD) patients...
Calcifying atherosclerosis is an active process, which is controlled by calcification inhibitors and...
Calcifying atherosclerosis is an active process, which is controlled by calcification inhibitors and...
Background and Objectives: Osteoprotegerin (OPG), a potent osteoclast activation inhibitor, decrease...
Biomarkers can help physicians identify subjects with an increased cardiovascular risk. Apart from t...
BACKGROUND:Fetuin A, a circulating inhibitor of ectopic calcification, is downregulated in hemodialy...